Ocugen

Dosing is complete in the third cohort of the OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States. Three subjects received a single subretinal administration of the highest dose (200 µL of 1.5x1011 vg/mL) being tested, which completed the dosing for the Phase 1 stage of the trial. The OCU410 ArMaDa clinical trial is being performed at 14 leading retinal surgery centers across the United States. For more information, read the full press release here: https://shorturl.at/nM0rf

Listen as Dr. David Birch, PhD., Scientific Director at Retina Foundation of the Southwest discusses the complexities of retinitis pigmentosa and its devastating impact on patients.

Keep your eyes safe this summer! Protect your eyes from harmful UV rays by wearing sunglasses and hats when outdoors! #UVEyeSafetyMonth #LoveYourEyes

Today, Dr. Benjamin Bakall, MD, PhD presented a late breaking abstract titled, “One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa” during a Hereditary Retinal Disease & Genetics Symposium at the American Society of Retina Specialists Annual Meeting in Stockholm, Sweden. The session was moderated by Dr. Rishi P. Singh, MD and Dr. Lejla Vajzovic, MD, FASRS —Chair of Ocugen’s Retina Scientific Advisory Board.

This preclinical pharmacological study performed by Neena Haider, Ph.D.'s team evaluated the effect of NR2E3 gene therapy in the rd7 animal model of retinal degeneration at various doses in early and intermediate stages of the disease. NR2E3 gene therapy improved photoreceptor survival, retinal function, and retinal structure at all dose levels. This effect was sustained for 6 months (study duration) after a single subretinal injection in both early and intermediate stage of the disease. This study highlights the therapeutic potential of NR2E3 modifier gene therapy for patients with retinitis pigmentosa (RP). https://lnkd.in/e7HbRter. #RP #GeneTherapy  

Ocugen Chief Medical Officer, Dr. Huma Qamar, addressed the significance of treating rare diseases--and meeting regional needs across the globe--during the most recent ADFO Summit. Ocugen is committed to shifting the treatment paradigm for inherited retinal diseases and grateful for the opportunity to share our clinical progress among new and meaningful audiences. #IRD #modifiergenetherapy #courageousinnovation

Ocugen has been included in the Lehigh University Pennsylvania 100 Index—a newly established stock index that aims to showcase the economic growth of Pennsylvania. The index comprises the 100 largest companies domiciled in Pennsylvania using a Free-Float Market-Capitalization methodology. We are honored to be recognized as one of the most prominent companies driving the progress of the state’s economic growth.   Visit https://lnkd.in/eAkhsTHG to learn more about the index, its methodology, and the companies that comprise it. Additionally, you can follow the project on LinkedIn at https://lnkd.in/eDXEcSZP.

Hear from a patient with retinitis pigmentosa (RP) who participated in the OCU400 Phase 1/2 clinical trial. RP is a group of rare, genetic disorders that involve a breakdown and loss of cells in the retina, leading to vision loss and blindness. Currently, RP is associated with mutations in more than 100 genes affecting nearly 300,000 people in the U.S. and Europe combined. There are no approved treatment options that slow or stop the progression of multiple forms of RP. OCU400 has the potential to bring hope to people living with RP. If you are interested in learning more about the OCU400 Phase 3 liMeliGhT clinical trial, contact: clinical.request@ocugen.com #RetinitisPigmentosa #IRD #genetherapy

Your vision matters! Join us in observing Eye Injury Prevention Month by wearing protective eyewear and prioritizing eye safety. #EyeInjuryPreventionMonth

Thanks @CGTLive for sharing the exciting news of the first patient dosed in our OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa. #RP #IRD